Raymond James Financial Services Advisors Inc. Has $3.85 Million Stake in Astrazeneca PLC (AZN)

Raymond James Financial Services Advisors Inc. grew its stake in shares of Astrazeneca PLC (NYSE:AZN) by 17.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,713 shares of the company’s stock after acquiring an additional 17,271 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Astrazeneca PLC were worth $3,853,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AZN. Meeder Asset Management Inc. bought a new stake in Astrazeneca PLC in the 2nd quarter worth about $105,000. WFG Advisors LP increased its holdings in Astrazeneca PLC by 36.0% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Astrazeneca PLC by 71.2% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after buying an additional 1,769 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Astrazeneca PLC by 18.4% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after buying an additional 846 shares in the last quarter. Finally, Westport Asset Management Inc. bought a new stake in Astrazeneca PLC in the 2nd quarter worth about $170,000. Hedge funds and other institutional investors own 14.44% of the company’s stock.

AZN has been the subject of several research analyst reports. Natixis upgraded Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Leerink Swann lifted their price objective on Astrazeneca PLC from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Argus reiterated a “buy” rating and issued a $35.00 price objective on shares of Astrazeneca PLC in a report on Friday, September 1st. Credit Suisse Group upgraded Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Astrazeneca PLC has an average rating of “Hold” and a consensus target price of $34.20.

COPYRIGHT VIOLATION NOTICE: “Raymond James Financial Services Advisors Inc. Has $3.85 Million Stake in Astrazeneca PLC (AZN)” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thestockobserver.com/2017/11/23/raymond-james-financial-services-advisors-inc-has-3-85-million-stake-in-astrazeneca-plc-azn.html.

Astrazeneca PLC (NYSE AZN) opened at $33.83 on Thursday. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market capitalization of $85,400.85, a PE ratio of 8.05, a PEG ratio of 3.19 and a beta of 0.75.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a return on equity of 34.02% and a net margin of 15.90%. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm earned $1.32 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. sell-side analysts predict that Astrazeneca PLC will post 1.93 earnings per share for the current year.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply